Can Celestica's Next-Generation HealthTech Portfolio Lift Its Shares?

Celestica's HealthTech portfolio—covering imaging, surgical equipment, diabetes care, diagnostics and connected devices—positions it to benefit from growing adoption of digital health, surgical robotics and advanced diagnostics. FY2026 EPS estimates rose 11.4% in 60 days to $11.32, while FY2027 estimates increased 30.2% to $19.01; the company holds a Zacks Rank #1 (Strong Buy). Shares have risen 39.1% over the past year but trail the industry's 50.1% gain, and CLS trades at 20.71x forward earnings versus the industry's 19.66x.

Analysis

The investable issue is not HealthTech exposure itself, but whether it can diversify CLS's earnings mix enough to lower the cyclicality and customer-concentration discount investors apply to an electronics manufacturer. Medical programs carry longer qualification cycles, higher switching costs and potentially steadier aftermarket revenue, but the article provides no evidence of incremental contract wins, segment revenue, backlog, or margin contribution. Until disclosed, this is narrative support rather than an estimate-changing catalyst.

JBL is the more credible near-term competitive threat: its scale can absorb customer supply-chain localization and offer bundled engineering/manufacturing economics, constraining CLS's ability to price HealthTech work at a premium. SANM could benefit disproportionately if demand shifts toward lower-volume, highly regulated programs where engineering depth matters more than global scale. The second-order beneficiary is not necessarily the contract manufacturer; established medtech OEMs such as ISRG, ABT and DXCM can use multi-source manufacturing to reduce launch and supply disruption risk, potentially retaining the bulk of cost savings.

Over the next 1-3 months, CLS needs a disclosed design win, HealthTech backlog metric, or evidence that segment mix lifts consolidated gross margin to justify further multiple expansion. Over 6-18 months, the structural upside depends on conversion from development engagements into serial production; failure to show this conversion would leave CLS exposed to a de-rating if its higher-growth end markets normalize. Falsify a constructive view on a material EPS-guide cut, gross-margin compression despite revenue growth, or evidence of share loss to JBL/SANM on regulated programs.

Contrarian view: consensus may be attributing improving estimates entirely to secular AI/datacenter demand, making HealthTech optionality largely irrelevant to the current valuation. That means a generic HealthTech narrative is unlikely to rerate CLS, while a tangible medical win could be a modest positive surprise; absent such proof, the cleaner expression is relative rather than outright.

Key Decisions for Investors

• No new outright CLS position on this article alone; place an alert for quarterly disclosure of HealthTech revenue, backlog, design wins, or segment margin. Upgrade only if management quantifies a path to material revenue within 12-24 months.
• Consider a 3-6 month relative-value watch: long SANM / short CLS if CLS continues to outperform without corresponding margin or backlog disclosure. Target a 10-15% relative return; stop if CLS reports a sizable regulated-medical program win or raises forward EPS guidance.
• For existing CLS longs, retain exposure only with a defined risk trigger: reduce on a quarterly gross-margin miss or forward-year EPS estimate reset exceeding 5%, since a premium multiple is vulnerable to mix disappointment.
• Monitor JBL's medical and supply-chain commentary at its next earnings release as a read-through for pricing. Evidence of accelerated regulated-device demand is sector-positive but would favor JBL unless CLS demonstrates superior program conversion.